Idiopathic Intracranial Hypertension (Highly Investigational)

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?

Not FDA-cleared for idiopathic intracranial hypertension. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.

¿Qué evidencia existe?

Tier C (highly investigational). No controlled trials. Evidence-based first-line management is weight loss (which is often disease-modifying), acetazolamide (the Idiopathic Intracranial Hypertension Treatment Trial showed superiority over placebo), topiramate as alternative, and for sight-threatening or refractory disease optic nerve sheath fenestration, CSF shunting (VP or LP shunt), or venous sinus stenting. Vision must be monitored urgently — papilledema with field loss is the principal threat.

Riesgos principales

• Bleeding from each bite site for 6 to 10 hours after the leech detaches
• Iron-deficiency anemia from cumulative blood loss across multiple sessions
• Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
• Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
• Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
• Local pain, bruising, swelling, or itching for 1 to 3 days after each session
• Vision-threatening disease — any delay in proven therapy risks permanent blindness
• No mechanistic plausibility for leech effect on CSF dynamics

Quién no debería considerar esto

• Patients with papilledema and visual-field loss (need urgent neuro-ophthalmologic and possibly surgical intervention)
• Patients who have not been started on acetazolamide and a weight-management plan
• Patients with secondary causes of intracranial hypertension that have not been worked up
• Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
• People with hemophilia or any other inherited bleeding disorder
• Patients with severe anemia (hemoglobin under 10 g/dL)
• People with an active infection at the planned application site

Qué preguntar a su clínico

• Have I been started on acetazolamide at therapeutic doses?
• Has my weight management plan been optimized — including consideration of bariatric surgery if BMI is high?
• What is my current visual field status, and how often will it be checked?
• Has venous sinus stenosis been excluded by MRV?
• If vision is at risk, should I have CSF shunting or optic nerve sheath fenestration?
• What is the published evidence base for leeches in IIH (likely none)?

Cuándo buscar atención urgente

• Bleeding from a bite site that soaks through more than one dressing per hour
• Bleeding that continues more than 24 hours after the leech detached
• Spreading redness, warmth, swelling, pus, or red streaks around any bite site
• Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
• Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
• Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
• Any new vision change — blurring, blackout, peripheral field loss, double vision
• Severe worsening of headache or new neurologic symptoms
• Pulsatile tinnitus worsening abruptly